Clinical Trial

A Phase II Clinical Study of HRS-1893 in Non-obstructive Hypertrophic Cardiomyopathy

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 5, 2025 (before its estimated August 2025 completion). Its status may not reflect the trial's current state.
Summary
This study mainly evaluated the safety and tolerability of HRS-1893 in subjects with non-obstructive hypertrophic cardiomyopathy, and the efficacy and plasma concentrations of different dosing regimens in subjects with non-obstructive hypertrophic cardiomyopathy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-04.
Status change: Not Yet Recruiting → Recruiting 2025-03-04
Trial Details
NCT Number NCT06816251
Lead Sponsor Shandong Suncadia Medicine Co., Ltd.
Conditions Non-obstructive Hypertrophic Cardiomyopathy
Enrollment 84 participants
Start Date 2025-02-25
Primary Completion 2025-08 (estimated)
Study Completion 2025-08 (estimated)
Updated on ClinicalTrials.gov 2025-03-05